CSL (CSLLY) AI Stock Analysis

CSL

(Other OTC:CSLLY)

Select Model

Rating:60Neutral

Price Target:$37.00▲(4.82% Upside)

Action:reiterated

Date:08/19/26

The overall score of 60 reflects a company in transition with significant operational headwinds offset by strong technical momentum and a stable financial foundation. The most impactful factor is the severe decline in reported profitability and the large impairments, which heavily weigh on the financial performance and valuation scores. However, strong bullish technical trends and management's credible plan for cost savings and a return to underlying earnings growth, as detailed in the earnings call, prevent a lower score. The high P/E ratio and modest dividend yield add a layer of valuation risk.

Positive Factors

Resilient cash generationStrong operating cash flow supports dividends, buybacks, investment, and debt service without relying solely on external funding. The 1.8x net-debt-to-EBITDA position also indicates that CSL retains meaningful financial flexibility while continuing to fund its biologics and vaccine businesses.

Negative Factors

Large impairments and statutory lossThe scale of impairments and the resulting statutory loss materially reduce confidence in the carrying value and earnings quality of recent investments. Even though the charges are largely noncash, they weaken the equity base and can constrain future capital allocation flexibility.

CSL (CSLLY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $136.89B
Dividend Yield: 2.03%
Average Volume (3M): 120.92K
Price to Earnings (P/E): -26.3
Beta (1Y): 0.28
Revenue Growth: 2.19%
EPS Growth: -187.48%
Country: US
Employees: 29,000
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CSL Business Overview & Revenue Model

Company Description

CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international...

How the Company Makes Money

CSL makes money primarily by selling high-value specialty biologic medicines and vaccines through three main business segments. (1) CSL Behring generates revenue from plasma-derived and recombinant therapies used to treat conditions such as immunodef...

CSL Earnings Call Summary

Earnings Call Date:Aug 16, 2026(Q4-2026)|% Change Since:49.31%|Next Earnings Date:Feb 08, 2027

Earnings Call SentimentNeutral

The call presents a mixed picture: operational and commercial turnaround actions are beginning to show early, tangible benefits (strong cash flow, successful transformation savings, Seqirus market outperformance, Ig momentum and promising product launches), but these positives are offset by very large impairments, significant and structural headwinds in Vifor (expected ~25% revenue decline in FY'27), continued albumin pricing pressure in China and an FY'26 statutory loss driven by noncash charges. Management’s FY'27 underlying guidance (NPAT +~5% cc; Behring growth) and capital returns indicate confidence in a return to profitable growth, yet the scale of recent impairments and the outlook for Vifor mean near-term headwinds remain material.

Positive Updates

Strong cash generation and capital returns

Operating cash flow of $3.5 billion supported completion of an AUD 1.0 billion share buyback, a new AUD 1.1 billion buyback authorization for FY'27, and maintenance of the full-year dividend at $2.92 per share (U.S. dollar basis); net debt/EBITDA finished at 1.8x within target range.

Negative Updates

Very large impairments and statutory loss

Total pretax impairments of $7.1 billion for FY'26 (including $5.5 billion in H2), with a $4.1 billion impairment primarily related to Vifor. After restructuring and impairments, statutory NPAT attributable to CSL shareholders was a loss of $2.6 billion.

Company Guidance

CSL guided FY '27 group revenue to be broadly in line with FY '26 (FY '26 revenue $15.8bn, -1% cc) and expects underlying NPAT (excluding restructuring and impairments) to grow by approximately 5% at constant currency (noting an estimated FX headwind of about $50m at current rates). By business, CSL Behring is expected to deliver mid‑single‑digit revenue growth with immunoglobulin growing mid‑ to high‑single digits and a modest gross‑margin improvement, Seqirus low‑single‑digit revenue growth, and CSL Vifor a ~25% revenue decline (no TAVNEOS sales included in guidance). The transformation program should deliver ~ $220m incremental savings in FY '27 (building on $176m delivered in FY '26) taking annualized savings to ~ $400m and up to $550m in FY '28, with roughly half the incremental savings to be reinvested; FY '27 CapEx is expected to be about $1.0bn ± $100m. Capital return and balance‑sheet items include a new share buyback of ~AUD 1.1bn, the dividend maintained in US$ (FY '26 full‑year $2.92 per share, final $1.62), and a target net‑debt/EBITDA range of 1.5–2x.

CSL Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is stable with manageable debt, and cash flow generation remains positive, providing financial flexibility. However, the income statement reveals a sharp decline in profitability, culminating in a substantial net loss for FY2026 due to significant impairments. This severe earnings erosion is a major concern, offsetting the company's solid liquidity and capital structure.

Income Statement

35Negative

Balance Sheet

65Positive

Cash Flow

60Neutral

Financial statement breakdown
Breakdown	TTM	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022
Income Statement
Total Revenue	15.74B	15.77B	15.43B	14.80B	13.17B	10.49B
Gross Profit	7.51B	7.52B	7.95B	7.56B	6.71B	5.66B
EBITDA	5.05B	5.07B	5.13B	4.74B	3.90B	3.46B
Net Income	-2.59B	-2.59B	3.00B	2.64B	2.19B	2.25B
Balance Sheet
Total Assets	33.65B	33.65B	39.40B	38.02B	36.23B	28.35B
Cash, Cash Equivalents and Short-Term Investments	1.51B	1.51B	2.16B	1.66B	1.55B	10.44B
Total Debt	10.90B	10.90B	11.50B	12.18B	12.23B	9.66B
Total Liabilities	17.34B	17.34B	18.00B	18.62B	18.41B	13.77B
Stockholders Equity	14.80B	14.80B	19.34B	17.36B	15.79B	14.58B
Cash Flow
Free Cash Flow	2.88B	2.88B	2.54B	1.51B	909.00M	1.38B
Operating Cash Flow	3.52B	3.53B	3.56B	2.76B	2.60B	2.63B
Investing Cash Flow	-1.28B	-1.28B	-850.00M	-1.26B	-11.84B	-1.64B
Financing Cash Flow	-2.84B	-2.84B	-2.24B	-1.28B	456.00M	7.68B

CSL Technical Analysis

Technical Analysis SentimentPositive

Last Price35.30

Price Trends

50DMA31.99Positive

100DMA26.81Positive

200DMA25.29Positive

Market Momentum

MACD1.10Negative

RSI76.82Negative

STOCH99.32Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSLLY, the sentiment is Positive. The current price of 35.30 is above the 20-day moving average (MA) of 33.47, above the 50-day MA of 31.99, and above the 200-day MA of 25.29, indicating a bullish trend. The MACD of 1.10 indicates Negative momentum. The RSI at 76.82 is Negative, neither overbought nor oversold. The STOCH value of 99.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CSLLY.

CSL Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CSLLY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	81Outperform	$95.51B	20.47	15.07%	0.38%	18.59%	8.14%
ARGX	76Outperform	$56.77B	41.24	16.86%	―	70.57%	30.28%
CSLLY	60Neutral	$67.36B	-26.32	-15.12%	2.03%	2.19%	-187.48%
BMRN	58Neutral	$11.33B	-638.22	1.18%	―	13.69%	-89.03%
BNTX	58Neutral	$22.15B	-11.56	-9.16%	―	-1.05%	-395.95%
MRNA	55Neutral	$88.52B	-27.67	-39.20%	―	-27.62%	-6.22%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

CSLLY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CSLLY	Csl Ltd	35.29	7.19	25.59%
BMRN	Biomarin Pharmaceutical Inc.	57.44	4.92	9.37%
REGN	Regeneron Pharmaceuticals	961.26	336.46	53.85%
ARGX	Argenx	874.97	43.49	5.23%
MRNA	Moderna	220.83	197.08	829.81%
BNTX	Biontech Se Sponsored Adr	87.53	-17.30	-16.50%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 19, 2026

CSL AI Stock Analysis